Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi - LARVOL DELTA

ALLOGENEIC STEM CELL TRANSPLANTATION FOR PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (EHA 2026) - "Three types of Busulfan-based conditioning regimen were used: Busulfan-Aracytine-Melphalan for 12 pts, Busulfan- cyclophosphamide-Etoposide for 15 pts, and Busulfan-Cyclophosphamide for 6 pts. For haplo-identical transplant, Busulfan- Aracytine-Cyclophosphamide and Thymoglobuline (Beijing Protocol) in 5 pts, Busulfan-Fludarabine-Thiotepa (TBF) in 15 pts...GVHD prophylaxis consisted on association of ciclosporine-methotrexate (HLA-identical sibling), ciclosporine-methotrexate-MMF (Beijing Protocol), and ciclosporine-MMF-PTCy (TBF)...Despite the use TKIs, we note à high rate of relapse. The advent of immunotherapy improves the results of transplantation due to better control of minimal residual disease"

Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pancreatitis • Transplantation • CD34

A PHASE II STUDY OF A BUSULFAN IN COMBINATION WITH FLAG CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETC STEM CELL TRANSPLANTATION (EHA 2026) - P4 | "Busulfan/Cyclophosphamide (BuCy, Cytarabine, Busulfan, Cyclophosphamide) has been a classical conditioning regimen for allo-SCT. Substitution of Cyclophosphamide in the BuCy regimen with Fludarabine (BuF) resulted in reduced toxicity and similar efficacy...In addition, patients with haploidentical or matched unrelated donors received rabbit anti-thymocyte globulin (ATG, Thymoglobuline) at 2.5 mg/kg/day on days -5 to -2...Median follow-up was 15 · 4 months (IQR 8 · 8-23 · 6) for patients treated with treosulfan and 17 · 4 months (6 · 3-23 · 4) for those treated with busulfan...The 2-year overall survival rates were 63.9% (95% CI: 53.3–72.6%) in all patients, 63.9% (95% CI:52.0%-73.6%) with AML and 64.4% (95% CI: 40.0%-80.9%) for those with MDS.T he 100-day cumulative incidence of acute graft-versus-host disease was 31.2% (95% CI: 22.7%–40.0%). . Summary/Conclusion This study provides evidence that busulfan/FLAG conditioning regimen may..."

Combination therapy • P2 data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome

THYMO B: Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients (clinicaltrials.gov) - P=N/A | N=49 | Completed | Sponsor: University Hospital, Brest | Unknown status ➔ Completed

Trial completion • Transplantation

Evaluation of 3 Different Doses of IV Busulfan (clinicaltrials.gov) - P2 | N=177 | Active, not recruiting | Sponsor: Institut Paoli-Calmettes | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

OUTCOMES OF ALLOGENEIC HSCT IN NIJMEGEN BREAKAGE SYNDROME WITH TREOSULFAN-BASED CONDITIONING REGIMEN - A MULTICENTER STUDY (EBMT 2026) - "We recently demonstrated experience of treosulfan 30g/m2 versus low doses of busulfan...All received fludarabine 150mg/m2, 24 cyclophosphamide (22–40mg/kg, 1–30mg/kg, 1–20mg/kg). In 37 patients, rabbit ATG (thymoglobulin, Genzyme) 3-7,5mg/kg, in 1 patient horse ATG (ATGAM) 100mg/kg, and in 2 patients no serotherapy was used.In 25 patients matched unrelated (19–10/10, 6–9/10 HLA-matched), in 9 mismatched related, in 6 matched sibling donor was used... Both doses of treosulfan 21g/m2 and 30g/m2 were well tolerated by NBS patients. However, lower dose of 21g/m2 was associated with higher risk of mixed chimerism and leukemia relapse versus increased incidence of secondary malignancy after higher dose of 30g/m2."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Metabolic Disorders • Primary Immunodeficiency • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Transplant Rejection

HUMANIZED ANTI‑CD25 MONOCLONAL ANTIBODY FOR GVHD PROPHYLAXIS IN ELDERLY HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION: A PHASE II STUDY (EBMT 2026) - P2 | "The standard GVHD prophylaxis protocol includes rATG+CNI+short-term MTX+mycophenolate mofetil. Patients in experimental group received humanized anti-CD25 mAb (50 mg/day, +1d, +4d) and reduced rATG (8mg/kg, Thymoglobuline)... Our study revealed that the addition of short‑course anti-CD25 prophylaxis (day +1, +4) in the rATG system proved feasible and safe. However, we did not observe its significant advantage in reducing severe acute or chronic GVHD. The benefit of extensive administration of anti-CD25 mAb warrants further investigation."

Clinical • P2 data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cardiovascular • Cerebral Hemorrhage • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

ATG EXPOSURE AND IMMUNE RECONSTITUTION IN CHILDREN WITH HEMOGLOBINOPATHIES FOLLOWING HSCT: DIFFERENT PATTERNS FOR ATG-GRAFALON AND THYMOGLOBULINE (EBMT 2026) - "Rabbit ATG preparations differ markedly in antibody spectrum and pharmacokinetics (PK), resulting in non-interchangeable exposure–response profiles. Eighty-six pediatric patients (90 HSCTs; 4 re-transplantations; median age 11.13 years) underwent transplantation for hemoglobinopathies (2011–2025) using treosulfan/fludarabine/thiotepa conditioning...In the ATLG cohort, 46.3% also received post-transplant cyclophosphamide (ptCy), which was associated with reduced severe cGvHD without evidence of impaired IR... ATG exposure is a key determinant of IR in pediatric hemoglobinopathy HSCT. ATLG and ATG-T display distinct PK/PD profiles, underscoring the need for individualized, product-specific exposure–response assessment. Weight-based dosing results in substantial variability, particularly in older children."

Clinical • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Immunology • Transplant Rejection • CD4 • CD8

SAFETY PROFILES OF TWO ANTI-THYMOCYTE GLOBULIN FORMULATIONS IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION: IMPLICATIONS FOR NURSING CARE (EBMT 2026) - "Currently, two main ATG formulations are used in clinical practice: Thymoglobulin® (rabbit-derived anti-human thymocyte immunoglobulin) and Grafalon® (anti-human T lymphocyte immunoglobulin). Grafalone demonstrated a more favorable safety profile during the first 72 hours of ATG infusion compared to Thymoglobuline. Its higher incidence of capillary leak and ICU transfer underscores the need for adequate nursing staffing and training to ensure patient safety. These findings should be interpreted with caution as they are based on preliminary data from a single center; results will be complemented by data from additional centers and multivariate analyses to control for confounding factors."

Clinical • Cardiovascular • Graft versus Host Disease • Hypertension • Hypotension • Immunology • Pediatrics • Transplantation

ULTRA-RAPID CD3/CD45RA-DEPLETED HAPLOIDENTICAL HSCT FOR PEDIATRIC CEREBRAL ALD: FEASIBILITY, ENGRAFTMENT KINETICS, CHIMERISM BEHAVIOR, AND EARLY NEUROLOGIC OUTCOMES IN THREE CASES (EBMT 2026) - "In parallel, lentiviral gene therapy (elivaldogene autotemcel) is an option for select early-stage patients, but eligibility, access, and time-to-treatment constraints frequently limit real-world use relative to the pace of inflammatory progression...Conditioning comprised ALC-based Thymoglobuline, model-based Fludarabine and Busulfan, Rituximab, and IVIG; GVHD prophylaxis included Tacrolimus... A standardized CD3/CD45RA-depleted haploidentical platform enabled rapid time-to-transplant, ultra-fast engraftment, and low GVHD in pediatric cALD. The recurrent observation of mixed/declining chimerism in early-stage patients—despite robust initial engraftment—highlights a potentially stage- and platform-specific behavior that may benefit from protocolized monitoring and timely DLI. These data support haploidentical HSCT as a timely, feasible option for cALD for multicenter evaluation to refine conditioning intensity, graft composition, and DLI strategies to optimize durable..."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Gene Therapies • Genetic Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Metabolic Disorders • Mucositis • Pediatrics

OUTCOMES OF ALLOGENEIC HSCT IN NIJMEGEN BREAKAGE SYNDROME WITH TREOSULFAN-BASED CONDITIONING REGIMEN - A MULTICENTER STUDY (EBMT 2026) - "We recently demonstrated experience of treosulfan 30g/m2 versus low doses of busulfan...All received fludarabine 150mg/m2, 24 cyclophosphamide (22–40mg/kg, 1–30mg/kg, 1–20mg/kg). In 37 patients, rabbit ATG (thymoglobulin, Genzyme) 3-7,5mg/kg, in 1 patient horse ATG (ATGAM) 100mg/kg, and in 2 patients no serotherapy was used.In 25 patients matched unrelated (19–10/10, 6–9/10 HLA-matched), in 9 mismatched related, in 6 matched sibling donor was used... Both doses of treosulfan 21g/m2 and 30g/m2 were well tolerated by NBS patients. However, lower dose of 21g/m2 was associated with higher risk of mixed chimerism and leukemia relapse versus increased incidence of secondary malignancy after higher dose of 30g/m2."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Metabolic Disorders • Primary Immunodeficiency • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Transplant Rejection

IN VIVO T CELL DEPLETION IN COMPLETE REMISSION ACUTE LEUKEMIA PATIENTS RECEIVING PERIPHERAL STEM CELL TRANSPLANTATION FROM HLA IDENTICAL SIBLING WITH MYELOABLATIVE CONDITIONING REGIMEN (EBMT 2026) - "ATG (Thymoglobuline) was administered at total dose of 5 mg/kg days -2 and -1... This retrospective single center study, with confounding factors due to the retrospective nature and low number of patients, show that ATG use, in HLAid sibling setting, improves the outcomes of AL. Only the CI of moderate/severe cGVHD was significant lower in ATG cohort."

Preclinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation

HUMANIZED ANTI‑CD25 MONOCLONAL ANTIBODY FOR GVHD PROPHYLAXIS IN ELDERLY HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION: A PHASE II STUDY (EBMT 2026) - P2 | "The standard GVHD prophylaxis protocol includes rATG+CNI+short-term MTX+mycophenolate mofetil. Patients in experimental group received humanized anti-CD25 mAb (50 mg/day, +1d, +4d) and reduced rATG (8mg/kg, Thymoglobuline)... Our study revealed that the addition of short‑course anti-CD25 prophylaxis (day +1, +4) in the rATG system proved feasible and safe. However, we did not observe its significant advantage in reducing severe acute or chronic GVHD. The benefit of extensive administration of anti-CD25 mAb warrants further investigation."

Clinical • P2 data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cardiovascular • Cerebral Hemorrhage • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

ATG EXPOSURE AND IMMUNE RECONSTITUTION IN CHILDREN WITH HEMOGLOBINOPATHIES FOLLOWING HSCT: DIFFERENT PATTERNS FOR ATG-GRAFALON AND THYMOGLOBULINE (EBMT 2026) - "Rabbit ATG preparations differ markedly in antibody spectrum and pharmacokinetics (PK), resulting in non-interchangeable exposure–response profiles. Eighty-six pediatric patients (90 HSCTs; 4 re-transplantations; median age 11.13 years) underwent transplantation for hemoglobinopathies (2011–2025) using treosulfan/fludarabine/thiotepa conditioning...In the ATLG cohort, 46.3% also received post-transplant cyclophosphamide (ptCy), which was associated with reduced severe cGvHD without evidence of impaired IR... ATG exposure is a key determinant of IR in pediatric hemoglobinopathy HSCT. ATLG and ATG-T display distinct PK/PD profiles, underscoring the need for individualized, product-specific exposure–response assessment. Weight-based dosing results in substantial variability, particularly in older children."

Clinical • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Immunology • Transplant Rejection • CD4 • CD8

FORUM2: Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. (clinicaltrialsregister.eu) - P2/3 | N=735 | Recruiting | Sponsor: Ospedale Pediatrico Bambino Gesu

New P2/3 trial • Bone Marrow Transplantation • Pediatrics • CD19 • KMT2A

Thymoglobuline and grafalon show comparable transplant outcomes in patients with aplastic anemia undergoing allogeneic stem cell transplantation: A multicenter EBMT saawp study of 1603 patients (ASH 2025) - "Introduction:Rabbit anti-thymocyte globulin (ATG) is a key component of conditioning regimens for patients withaplastic anemia (AA) undergoing allogeneic hematopoietic stem cell transplantation (HSCT).Thymoglobuline (Thymo) is widely regarded as the standard formulation due to its extensive clinicaladoption and inclusion in international guidelines, while Grafalon (Grafa) is also commonly used inclinical practice. In this large, registry-based cohort of AA patients undergoing HSCT, no significant differences wereobserved in OS, GF, GVHD incidence, or GRFS between Thymo and Grafa. However, Grafalon dosageappeared to influence outcomes, particularly with respect to chronic GVHD. These findings support theclinical equivalence of both rabbit ATG formulations in the setting of HSCT and suggest that ATG selectioncan be guided by institutional preference or availability without compromising patient outcomes."

Clinical • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation

The impact of HLA loss of heterozygosity on outcome after haploidentical hematopoietic stem cell transplantation in hematological malignancies (ASH 2025) - "Allpatients received haplo-HSCT; pre-transplant disease status was CR (80.0%, n=36) or NR (20.0%, n=9).Conditioning regimens were busulfan (Bu)-cyclophosphamide (Cy) (66.7%), total body Irradiation (TBI)-Cy(17.8%), Bu-fludarabine (flu) (13.3%), or TBI-flu (2.2%). ATG-fresenius (ATG-F) or ATG-thymoglobuline(ATG-T) were used for GVHD prophylaxis... Second transplantation improves survival in patients experiencing relapse following haplo-HSCT who demonstrate HLA loss. Survival outcomes were independent of HLA loss pattern (haplotype vs.locus-specific) or extent (number of loci lost). Poor prognostic factors were pre-transplant NR status andthe use of TBI-based conditioning."

IO biomarker • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Liver Failure • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • HLA-B • HLA-C • HLA-DQB1 • HLA-DRB1

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT (ASH 2024) - "Background Prospective randomized trials have reported a benefit for anti-thymoglobuline (ATG)-based graft-versus-host disease (GvHD) prophylaxis in the setting of allogeneic hematopoietic stem cell transplantation (alloHSCT) using unrelated donors (UD)...Cox (cause-specific) proportional hazards models were used to obtain adjusted estimates of the effect of PTCY compared to ATG on all endpoints, with a predefined set of adjustment factors (age, DIPSS, donor HLA matching, prior ruxolitinib, comorbidity score, MF subtype (PMF vs sMF)) and a frailty term for transplant center...PTCY is a valid option and considering availability and costs of ATG this may offer a good choice/alternative for regions which do have difficulties to have access to ATG. However, engraftment remains an issue in this setting."

Clinical • Post-transplantation • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Myelofibrosis • Oncology • Transplantation

Sequential Conditioning Regimen with Thiotepa, Clofarabine and Busulfan (TEC/CloB2A2) and Post-Transplant Cyclophosphamide in Adults with Refractory AML: A Retrospective Monocentric Study (ASH 2023) - "Recently, a combination of thiotepa, etoposide, cyclophosphamide (TEC) followed by fludarabine/busulfan/ATG (FB2A2) using any type of donor for refractory hematologic malignancies have shown some promising results (Dulery, 2018)...The TEC/CloB2A2 regimen consisted of Thiotepa 5 mg/kg at day(d)-13, Cyclophosphamide 400 mg/m²/d from d-12 to d-9 and Etoposide phosphate 100 mg/m²/d from d-12 to d-9, followed after 3 days of rest, by Clofarabine 30 mg/m²/d from d-5 to d-1, Busulfan 3,2 mg/kg/d d-5 and d-4 and Thymoglobuline 2,5 mg/kg/d d-3 and d-2. GVHD prophylaxis consisted of high-dose of post-transplant Cyclophosphamide (PTCY) 50 mg/kg/d at d+3 and d+5 in combination with mycophenolate mofetyl and cyclosporine starting at d+6...Six out of 8 CR/CRp patients received maintenance treatment after transplant to prevent relapse using 5'azacytidine alone in 1, 5 azacytidine+ donor lymphocyte infusion (DLI) in 2, DLI alone in 1... The sequential TEC/CloB2A2..."

Post-transplantation • Retrospective data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Acute Respiratory Distress Syndrome • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Septic Shock • Transplantation

Up-Front Matched Unrelated Donor Transplantation in Pediatric Patients with Idiopathic Aplastic Anemia: A Phase II Feasibility Study, on Behalf of Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and French Reference National Center of Severe Aplastic Anemia (ASH 2024) - "Conditioning regimen was fludarabine (30mg/m2/d) and cyclophosphamide (30mg/m2/d) D-6 to D-3 and either anti-thymoglobuline (Genzyme, France) 15mg/kg TD or total body irradiation 2Gy + ATG 7,5mg/kg TD depending on the age, below 14y or above. GvHD prophylaxis was ciclosporine A from D-1 to D365 associated to methotrexate 8mg/m2 D+1,+3 and+6...Finally, up-front HSCT from MUD for pts below the age of 18y presenting with SAA appears safe when the donor is available within 75-90 days. Rituximab is mandatory to lower the risk of EBV-PTLD for both prophylaxis and early pre-emptive treatment.If the donor recruitment is delayed, immune-suppressive therapy has to be preferred and promptly started."

Clinical • P2 data • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pediatrics • Transplantation

BISPECIFIC ANTIBODIES FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS RESCUE THERAPY IN REFRACTORY/RELAPSE NON-HODGKIN LYMPHOMA (SIE 2025) - "Eight pts (4 females and 4 males) with RR lymphomas (4 DLBCL, 3 FL and 1 MCL) received HSCT after treatment with glofitamab (4 pts), mosunetuzumab (3 pts) and epcoritamab (1 pts)...Most pts (7/8, 87%) received matched unrelated donors' transplants with TCF (Thiotepa, cyclophosphamide and fludarabine) conditioning regimen and ATG thymoglobuline as GVHD prophylaxis (Table 1)...Six pts achieved CR after steroid treatment while one pts progressed and died due to hepatic aGVHD refractory to steroid and ruxolitinib...This pts rapidly suspended immunosuppressive therapy without aGVHD reactivation and is still alive after venetoclax savage therapy...Table 1. Patient characteristics."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

Prevention of CMV and BKV in De Novo Kidney Transplant Recipients Immunosuppressed with the Combination of Low Dose Tacrolimus and Everolimus (WTC 2025) - "Thymoglobuline induction was given to both the study groups... In conclusion, our data show the safety and efficacy of long-term immunosuppression in renal transplant recipients treated with the combination of EVR plus low dose TAC. We found significantly lower CMV and BK virus infections and significantly lower acute rejection in the EVE + low dose TAC group, respect to the standard TAC plus MMF immunosuppression."

Clinical • Cytomegalovirus Infection • Infectious Disease • Nephrology • Transplant Rejection • Transplantation

OPTIMIZED CONDITIONING REGIMEN ENHANCES TCRαß+ CELL DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION ENGRAFTMENT IN PATIENTS WITH THALASSEMIA MAJOR (EHA 2025) - ".Conditioning Regimens: The conditioning regimens were divided into two groups: TDH-A Group: Anti-thymocyte globulin (ATG) administered on days -8 to -7 without cyclophosphamide (Cy) on days - and/or -1; and TDH-B Group: ATG administered on days - 1 to -19 with 50mg/kg Cy on day - and/or an additional 5mg/kg Cy on day -1.Other conditioning steps were identical: - Days - 1 to -19: Thymoglobuline (rATG Sanofi France) 5mg/kg...- Days -6 to -4: Busulfan 90-100mg/m² (adjusted to maintain steady-state serum levels of 500-700 mg/L). - Days -6 to - : Fludarabine 40mg/m². - Day -3: Thiotepa 10mg/kg...GVHD Prophylaxis: Short-term (<6 months) low-dose tacrolimus or sirolimus with or without mycophenolate mofetil... ATG exhibits a bidirectionality of influences on engraftment dependent on timing. Pre-d0 (transplant day) ATG administration enhances engraftment while post-d0 use impairs it. Advancing ATG to day - 1 significantly promoted engraftment.Pre-transplant DLI..."

Clinical • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hepatology • Immunology • Transplantation

Study of efficacy and safety of eltrombopag in combination with rabbit anti-thymocyte globulin and cyclosporine A in treatment naive East-Asian patients with severe aplastic anemia (clinicaltrialsregister.eu) - P2 | N=36 | Sponsor: Novartis

New P2 trial • Anemia • Aplastic Anemia • Hematological Disorders

Allograft-Educated Platelets for Gene Profiling of Acute Rejection After Heart Transplantation (ISHLT 2025) - P | "The recipients received induction with thymoglobuline, followed by tacrolimus, mycophenolic mofetil, and prednisolone maintenance immunosuppression...Initial findings also show that platelet gene expression profiling can accurately detect occurrence and severity of acute cellular rejection following heart transplantation (Figure 1).Conclusion This study proposes a novel approach to diagnosing acute rejection in heart transplant recipients. By directly comparing dd-cfDNA levels and the platelet transcriptome with EMB transcriptomics, the research aims to confirm the efficacy of non-invasive methods, improve diagnostic accuracy, reduce patient burden from surveillance EMB, and enhance long-term outcomes in heart transplantation."

Oncology • Transplant Rejection • Transplantation

BISPECIFIC ANTIBODIES FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS RESCUE THERAPY IN REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: REAL-LIFE EXPERIENCE IN CART AND TARGET THERAPY ERA (EBMT 2025) - " Six patients (4 females and 2 males) with RR lymphomas (3 follicular lymphomas, 2 diffuse B-cell lymphomas and 1 mantle cell lymphoma) received HSCT after treatment with mosunetuzumab (3 pts) or glofitamab (3 pts)...Pts received a median of 8 (4-12) doses (cycles) of BiAb; 4 pts had previously progressed after CAR-T cell therapy (4 Tisagenlecleucel, 1 Brexucbtagene autoleucel) while 2 pts were refractory to target therapy...One pts received haploidentical transplant with post- cyclophosphamide GVHD prophylaxis while 5 pts received matched unrelated donors' transplants with GVHD prophylaxis based on ATG thymoglobuline...Five patients were treated with steroid: 4 patients achieved CR while the other one died due to hepatic aGVHD despite refractory to steroid and ruxolitinib... in our experience, bridging with BiAb to HSCT in 6 pts who failed CAR-T or target therapies achieved a response in all pts before transplant and allowed a safe HSCT with only 1 NRM event and..."

Clinical • Acute Graft versus Host Disease • B Cell Lymphoma • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation